Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 12/20 | 0.53 |
| ▸ | LPAR5 | Q9H1C0 | 4/20 | 0.53 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.53 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.53 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.53 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.53 |
| ▸ | LPAR6 | P43657 | 2/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.53 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 2/20 | 0.39 |
| ▸ | P2RY10 | O00398 | 2/20 | 0.38 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.38 |
| ▸ | GPR34 | Q9UPC5 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9905960 | 0.86 | LPAR1 (0.64) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL29438567 | 0.86 | LPAR1 (0.64) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL9905935 | 0.84 | LPAR1 (0.72) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL31442359 | 0.83 | LPAR1 (0.78) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL18744459 | 0.82 | LPAR1 (0.58) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL6346455 | 0.82 | LPAR1 (0.80) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL13409099 | 0.82 | LPAR1 (0.80) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL6345706 | 0.82 | LPAR1 (0.80) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL6340011 | 0.82 | LPAR1 (0.80) | LPAR1LPAR5LPAR4LPAR2LPAR3 | |
| SCHEMBL9905951 | 0.82 | LPAR1 (0.80) | LPAR1LPAR5LPAR4LPAR2LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | claimed |
| US-6911553-B1 | Osteoblast-specific mitogens and drugs containing such compounds | ROCHE DIAGNOSTICS GMBH (DE) | 2005-06-28 | — | — | US | disclosed |
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | ESSWEIN ANGELIKA (DE) | 2005-01-20 | — | — | US | disclosed |
| EP-1019062-B1 | OSTEOBLAST-SPECIFIC MITOGENS AND DRUGS CONTAINING SUCH COMPOUNDS | ROCHE DIAGNOSTICS GMBH (DE) | 2003-02-05 | — | — | EP | disclosed |
| US-6197759-B1 | ADMINISTERING LYSOPHOSPHATIDYLIC ACID DERIVATIVE | ROCHE DIAGNOSTICS GMBH (DE) | 2001-03-06 | — | — | US | disclosed |
| EP-0906759-A1 | Novel osteoblastic specific mitogenes: process for their preparation and drugs containing these compounds | Roche Diagnostics GmbH (DE) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014723-A1 | Osteoblast-specific mitogens and drugs containing such compounds | LPAR1, LPAR2, LPAR4 | LPAR1 1/4885LPAR5 5/4885LPAR4 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.